Lobe Sciences Ltd

Company Profile

Lobe Sciences Ltd had its IPO on under the ticker symbol LOBEF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Lobe Sciences Ltd has a staff strength of 0 employees.

Stock update

Shares of Lobe Sciences Ltd opened at $0 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0 - $0, and closed at $0.

This is a +21.43% increase from the previous day's closing price.

A total volume of 31,800 shares were traded at the close of the day’s session.

In the last one week, shares of Lobe Sciences Ltd have increased by 0%.

Lobe Sciences Ltd's Key Ratios

Lobe Sciences Ltd has a market cap of $3.76 million, indicating a price to book ratio of 0.7597 and a price to sales ratio of 7.7249.

In the last 12-months Lobe Sciences Ltd’s revenue was $884837 with a gross profit of $841556 and an EBITDA of $-4112988. The EBITDA ratio measures Lobe Sciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lobe Sciences Ltd’s operating margin was 0% while its return on assets stood at -79.03% with a return of equity of -340.32%.

In Q0.66666666666667, Lobe Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Lobe Sciences Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lobe Sciences Ltd’s profitability.

Lobe Sciences Ltd stock is trading at a EV to sales ratio of 5.9486 and a EV to EBITDA ratio of 1.5859. Its price to sales ratio in the trailing 12-months stood at 7.7249.

Lobe Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.17 million

Total Liabilities

$1.99 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Lobe Sciences Ltd ended 2024 with $1.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.17 million while shareholder equity stood at $-815861.00.

Lobe Sciences Ltd ended 2024 with $0 in deferred long-term liabilities, $1.99 million in other current liabilities, in common stock, $-33994434.00 in retained earnings and $0 in goodwill. Its cash balance stood at $172565.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Lobe Sciences Ltd’s total current assets stands at $478428.00 while long-term investments were $665524.00 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Lobe Sciences Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Lobe Sciences Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0

52-Week High

$0.185

52-Week Low

$0.0013

Analyst Target Price

$

Lobe Sciences Ltd stock is currently trading at $0 per share. It touched a 52-week high of $0.185 and a 52-week low of $0.185. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.02 and 200-day moving average was $0.03 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 253.3% of the company’s stock are held by insiders while 0% are held by institutions.